BioSpace News Archive

Business

ADC Therapeutics and Adagene Team Up to Develop Anti-Cancer Molecules

ADC Therapeutics, based in Lausanne, Switzerland, and Adagene, headquartered in Suzhou, China and San Francisco, announced a discovery collaboration and license deal.

April 24, 2019
·
2 min read
·
Mark Terry
Business

ADC Therapeutics and Adagene Announce License Agreement

ADC Therapeutics to develop next-generation masked antibody drug conjugates (ADCs), incorporating Adagene’s SAFEbody™ technology, with potential utility across multiple tumor types

April 24, 2019
·
4 min read
Thiazide diuretics reduced the risk of fractures in people with Alzheimer’s disease

The use of thiazide diuretics was associated with a decreased risk of low energy fractures in people with Alzheimer’s disease, a new study from the University of Eastern Finland shows.

April 24, 2019
·
1 min read
Business

CDMO Yposkesi appoints new Director of Viral Vector Manufacturing Operations

With 15 years’ bioproduction and cell & gene therapy expertise, Morad El Gueddari will take charge of Yposkesi’s industrial-scale viral vector manufacturing

April 24, 2019
·
2 min read
Cytura Therapeutics to Develop a New Class of Drugs Targeting genomic instability in cancer

Cytura Therapeutics announces the successful closure of a Seed financing round.

April 24, 2019
·
3 min read
Yposkesi chairman Dr. Frederic Revah to speak on ‘Manufacturing and the CDMO Perspective’

Dr. Revah will join fellow industry panelists at the Cell and Gene Meeting on the Med in Barcelona to discuss strategies for gene therapy manufacturing, on April 23rd

April 24, 2019
·
2 min read
Karolinska Development’s portfolio company Dilafor secures financing for continued development of tafoxiparin

Karolinska Development AB announces that its portfolio company Dilafor AB has completed a capital raising and is planning to start a new Phase 2b study of tafoxiparin to soften the cervix prior to labor induction.

April 24, 2019
·
4 min read
Drug Development

Galapagos and MorphoSys announce initiation of GECKO Phase 2 study with MOR106 in atopic dermatitis patients

Galapagos NV, MorphoSys AG and Novartis Pharma AG announced the initiation of GECKO, a Phase 2 study testing a subcutaneous formulation of MOR106 in combination with topical corticosteroids in patients with moderate to severe atopic dermatitis.

April 24, 2019
·
6 min read
Pharm Country

Despite a Q1 Drop in Sales, J&J Anticipates New Indications Will Increase Xarelto Revenue Growth

Life sciences giant blamed the Medicare “doughnut hole” and increased competition for the blood thinner’s declining sales.

April 24, 2019
·
2 min read
·
Alex Keown
Drug Development

Soligenix - Advancing to Important Inflection Points With Two Pivotal Phase 3 Clinical Trials - April 23, 2019

Soligenix, Inc. issued an update letter from its President and Chief Executive Officer, Dr. Christopher J. Schaber.

April 24, 2019
·
14 min read